Literature DB >> 18635004

Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.

Claudia M Dollins1, Smita Nair, David Boczkowski, Jaewoo Lee, Juliana M Layzer, Eli Gilboa, Bruce A Sullenger.   

Abstract

We show that a molecular scaffold can be utilized to convert a receptor binding aptamer into a receptor agonist. Many receptors (including tumor necrosis receptor family members) are activated when they are multimerized on the cell surface. Molecular scaffolds have been utilized to assemble multiple receptor binding peptide ligands to generate activators of such receptors. We demonstrate that an RNA aptamer that recognizes OX40, a member of the tumor necrosis factor receptor superfamily, can be converted into a receptor-activating aptamer by assembling two copies on an olignucleotide-based scaffold. The OX40 receptor-activating aptamer is able to induce nuclear localization of nuclear factor-kappaB, cytokine production, and cell proliferation, as well as enhance the potency of dendritic cell-based tumor vaccines when systemically delivered to mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635004      PMCID: PMC2525512          DOI: 10.1016/j.chembiol.2008.05.016

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  31 in total

1.  C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L.

Authors:  Sylvie Fournel; Sébastien Wieckowski; Weimin Sun; Nathalie Trouche; Hélène Dumortier; Alberto Bianco; Olivier Chaloin; Mohammed Habib; Jean-Christophe Peter; Pascal Schneider; Bernard Vray; René E Toes; Rienk Offringa; Cornelis J M Melief; Johan Hoebeke; Gilles Guichard
Journal:  Nat Chem Biol       Date:  2005-12       Impact factor: 15.040

2.  The crystal structure of the costimulatory OX40-OX40L complex.

Authors:  Deanne M Compaan; Sarah G Hymowitz
Journal:  Structure       Date:  2006-08       Impact factor: 5.006

Review 3.  Immunostimulatory monoclonal antibodies for cancer therapy.

Authors:  Ignacio Melero; Sandra Hervas-Stubbs; Martin Glennie; Drew M Pardoll; Lieping Chen
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

4.  Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.

Authors:  Smita Nair; David Boczkowski; Martin Fassnacht; David Pisetsky; Eli Gilboa
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

5.  Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.

Authors:  Andrew D Weinberg; Colin Thalhofer; Nick Morris; Joshua M Walker; Donald Seiss; Scott Wong; Michael K Axthelm; Louis J Picker; Walter J Urba
Journal:  J Immunother       Date:  2006 Nov-Dec       Impact factor: 4.456

6.  Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Authors:  Nicholas P Morris; Carmen Peters; Ryan Montler; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Andrew D Weinberg
Journal:  Mol Immunol       Date:  2007-03-19       Impact factor: 4.407

Review 7.  TNF/TNFR family members in costimulation of T cell responses.

Authors:  Tania H Watts
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

8.  A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.

Authors:  Shahid M Nimjee; J R Keys; G A Pitoc; G Quick; C P Rusconi; Bruce A Sullenger
Journal:  Mol Ther       Date:  2006-06-09       Impact factor: 11.454

9.  First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.

Authors:  Christopher K Dyke; Steven R Steinhubl; Neal S Kleiman; Richard O Cannon; Laura G Aberle; Min Lin; Shelley K Myles; Chiara Melloni; Robert A Harrington; John H Alexander; Richard C Becker; Christopher P Rusconi
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

10.  Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection.

Authors:  Juliana M Layzer; Bruce A Sullenger
Journal:  Oligonucleotides       Date:  2007
View more
  71 in total

1.  Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.

Authors:  Erin E Soule; Kristin M Bompiani; Rebecca S Woodruff; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2015-11-19       Impact factor: 5.486

2.  Nucleotide bias observed with a short SELEX RNA aptamer library.

Authors:  William H Thiel; Thomas Bair; Kristina Wyatt Thiel; Justin P Dassie; William M Rockey; Craig A Howell; Xiuying Y Liu; Adam J Dupuy; Lingyan Huang; Richard Owczarzy; Mark A Behlke; James O McNamara; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-06-28       Impact factor: 5.486

Review 3.  Aptamer-Mediated Delivery and Cell-Targeting Aptamers: Room for Improvement.

Authors:  Amy C Yan; Matthew Levy
Journal:  Nucleic Acid Ther       Date:  2018-06       Impact factor: 5.486

4.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

Review 5.  An RNA toolbox for cancer immunotherapy.

Authors:  Fernando Pastor; Pedro Berraondo; Iñaki Etxeberria; Josh Frederick; Ugur Sahin; Eli Gilboa; Ignacio Melero
Journal:  Nat Rev Drug Discov       Date:  2018-09-07       Impact factor: 84.694

Review 6.  Aptamers as Therapeutics.

Authors:  Shahid M Nimjee; Rebekah R White; Richard C Becker; Bruce A Sullenger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-01-06       Impact factor: 13.820

Review 7.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

8.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01

9.  Composite RNA aptamers as functional mimics of proteins.

Authors:  Daiying Xu; Hua Shi
Journal:  Nucleic Acids Res       Date:  2009-04-20       Impact factor: 16.971

10.  An RNA-based transcription activator derived from an inhibitory aptamer.

Authors:  Shengchun Wang; Jason R E Shepard; Hua Shi
Journal:  Nucleic Acids Res       Date:  2010-01-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.